Abstract Although therapeutic HPV vaccines are able to elicit systemic HPV-specific immunity, clinical responses have not always correlated with levels of vaccine-induced CD8
Introduction
In the past decade, significant evidence has established human papillomavirus (HPV) as the causative agent in a growing proportion of incident cases of head and neck cancers. It is estimated that HPV is a causative agent in up to 80 % of oropharyngeal cancers in the United States [1] . HPV type is the most prevalent viral type and is present in greater than 90 % of HPV-associated head and neck squamous cell carcinomas (HPV-HNSCCs). HPVHNSCCs have favorable clinical outcomes with survival rates of 82 % at 3 years compared to 57 % in non-HPVHNSCCs [2] . Given these improved survival rates, the field is transitioning into a new phase that focuses not only on achieving cure but improving the quality of life through de-escalation treatment protocols. In this setting, therapeutic HPV vaccines may have a role as adjuvant therapy. Since the HPV viral oncoproteins, E6 and E7, are required for the induction and maintenance of the malignant phenotype, these proteins are constitutively expressed by cancer cells and thus represent ideal targets for immunotherapeutic strategies [3] .
Therapeutic vaccines against HPV-16 have been administered to humans in clinical trials and have demonstrated that systemic CD8
? T-cell responses against the HPV viral oncoproteins, E6 and E7, can be elicited through vaccination [4] [5] [6] . However, clinical responses have not necessarily correlated with the levels of vaccine-induced tumor-specific T cells. Possible explanations for this observation include the presence of an immunosuppressive tumor microenvironment into which the elicited T cells are recruited. Therefore, a variety of immunomodulatory agents, which target different immunosuppressive cell populations, have been evaluated [7, 8] . One such agent is cyclophosphamide (CTX), which is an alkylating agent with relatively low toxicity. When given in immune modulatory doses, CTX demonstrated a synergistic effect on T cell-mediated antitumor responses in both preclinical and clinical studies [9] [10] [11] [12] [13] . A principal means by which this is achieved is through the targeting of the inhibitory CD4
? CD25 ? FoxP3 ? regulatory T cells (Tregs) [9, 14, 15] . Tregs can dampen tumor-specific immune responses by suppressing effector CD8
? T-cell function and have been found in increased frequency in the peripheral blood and tumor microenvironment of a variety of solid tumors, including head and neck squamous cell carcinomas [16, 17] . However, an optimal dosing regimen of CTX in combination with vaccines to eradicate the Treg population without adversely affecting vaccine-induced T-cell responses has yet to be determined.
In this study, we performed a systematic comparison between daily-and single-dose administrations of CTX in combination with a therapeutic HPV DNA vaccine. We first performed a dose titration of daily administration of CTX and then compared daily-and single-dose administration in combination with an HPV vaccine in the TC-1 tumor model to determine the optimal immunomodulatory dosing regimen for translation for human application.
Materials and methods

Mice
C57BL/6 mice (5 to 8 week old) were purchased from the National Cancer Institute (Frederick, MD). All animals were maintained under specific pathogen-free conditions, and all procedures were performed according to an approved animal protocol (JHU ACUC #MO07M481) and in accordance with recommendations for the proper use and care of laboratory animals.
Peptides, antibodies, and reagents
The H-2D b -restricted HPV16 E7aa49-57 peptide, RAH-YNIVTF, was synthesized by Macromolecular Resources (Denver, CO) at a purity of C80 %. FITC-conjugated rat anti-mouse CD4 (clone RM4-5), PE-conjugated antimouse Foxp3 (clone FJK-16s), FITC-conjugated antimouse Gr-1 (clone RB6-8C5), and PE-conjugated anti-mouse CD11b (clone M1/70) antibodies were purchased from eBioscience (San Diego, CA). FITCconjugated rat anti-mouse IFN-c (clone XMG1.2), APCconjugated anti-CD3 (clone 17A2), FITC and PE-conjugated anti-mouse CD8a (clone 53.6.7) antibodies were purchased from BD Pharmingen (BD Pharmingen, San Diego, CA). Cyclophosphamide was purchased from Sigma and dissolved in phosphate-buffered saline (PBS) and stored at -20°C before use. Cells HPV-16 E6 and E7-expressing TC-1 tumor cells were generated as previously described by transforming primary C57BL/6 mice lung epithelial cells with HPV-16 E6, E7, and ras oncogenes [18] . TC-1 has been reliably used as a preclinical model to study HPV16 E7-specific CD8
? T-cell responses for the evaluation of therapeutic HPV vaccines to support Phase I clinical trials in human subjects [19] . The cells were maintained in RPMI medium supplemented with 2 mM glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin, 100 lg/ml streptomycin, and 10 % fetal bovine serum.
DNA vaccine
The construction of the DNA vaccine, pNGVL4a-CRT/ E7(detox), has been described previously [19] . E7(detox) represents a HPV16 E7 gene with mutations at positions 24 and 26, which disrupts the Rb-binding site of E7 and, thus, abolishes the capacity of E7 to transform cells [20] . The plasmid backbone, pNGVL-4a, was obtained from the NIH National Gene Vector Laboratory and is a human approved vector [21] . Clinical grade pNGVL4a-CRT/E7(detox) plasmid was prepared by NIH Rapid Access to Interventional Development (RAID).
In vivo tumor treatment with low-dose cyclophosphamide and DNA vaccination For the in vivo tumor treatment experiments, 1 9 10 5 TC-1 tumor cells were injected into 5-to 8-week-old C57BL/6 mice (five to ten per group) subcutaneously (s.c.) in the right flank. For the CTX treatment experiments, the mice were injected with CTX via intraperitoneal (i.p.) injection at various dosing schedules that included either daily administration or administration 1 day prior to each DNA vaccination. For the DNA vaccination experiments, the mice were vaccinated with 2 lg/mouse of pNGVL4a-CRT/ E7(detox) via intramuscular (i.m.) injection followed by electroporation as previously described [22] 9 days after tumor inoculation. Subsequently, the mice were boosted at 1-week intervals for a total of three vaccinations. Mice were monitored for tumor growth by measuring tumor diameter with calipers twice a week. Tumor volume was calculated using the formula [largest diameter 9 (perpendicular diameter) 2 ] 9 3.14/6. To record the survival of the tumor-bearing mice, either natural death or a tumor diameter greater than 2 cm leading to death was counted as death.
Preparation of single-cell suspensions from TC-1 tumors One week after the last vaccination, TC-1 tumors were surgically excised using sterile technique, placed in RPMI-1640 medium containing 100U/ml penicillin and 100 lg/ml streptomycin and washed with PBS. The solid tumors were then minced into 1-to 2-mm pieces and immersed in serum-free RPMI-1640 medium containing 0.05 mg/ml collagenase I, 0.05 mg/ml collagenase IV, 0.025 mg/ml hyaluronidase IV, 0.25 mg/ml DNase I, 100 U/ml penicillin, and 100 lg/ml streptomycin and incubated at 37°C with periodic agitation. The tumor digest was then filtered through a 70-lm nylon filter mesh to remove undigested tissue fragments. The resultant single tumor cell suspensions and tumor-infiltrating lymphocytes were washed twice in Hank's buffered salt solution (HBSS) (400g for 10 min), and viable cells were determined using trypan blue dye exclusion.
Flow cytometric analysis
For the detection of Tregs, single-cell preparations from mouse spleen and tumor were resuspended in FACS staining buffer (0.5 % BSA in PBS) and incubated with anti-CD4-FITC and CD25-APC antibodies for 30 6 ) or single-cell suspensions of TC-1 tumors (2 9 10 6 ) from each experimental group were incubated for 20 h with 1 lg/ml of HPV16 E7aa49-57 peptide in the presence of 1 lg/ml GolgiPlug (BD Pharmingen, San Diego, CA). The stimulated cells were washed with FACS buffer and stained with PE-conjugated anti-mouse CD8a. The cells were fixed using the Cytofix/ Cytoperm kit according to the manufacturer's instruction (BD Pharmingen, San Diego, CA). Staining for intracellular IFN-c was performed with FITC-conjugated antimouse IFN-c. Flow cytometry analysis was performed using FACSCalibur with CELLQuest software.
Statistical analysis
Data expressed as means ± standard deviations (SD) are representative of at least two separate experiments. Comparisons between individual data points were made by two-tailed Student's t-test. Data for tumor treatment experiments were evaluated by analysis of variance (ANOVA). Survival distributions for mice in different groups were compared by the Kaplan-Meier curves and by use of the log-rank tests. A p value of less than 0.05 was considered statistically significant.
Results
Single-dose cyclophosphamide enhances antitumor effects of CRT/E7 DNA vaccine
Tumor-infiltrating lymphocytes (TILs) from head and neck cancer patients have been reported to contain high levels of CD4
? CD25 ? Foxp3 ? Tregs when compared to autologous PBMC [17] . In order to confirm this observation in HPV-HNSCC, we evaluated the frequency of Tregs in the tumors and PBMC of patients with HPV-HNSCC as well patients with chronic tonsillitis, which served as non-cancer controls (Supplementary Figure 1) . HPV-HNSCC patients contained higher frequencies of CD4
?
Tregs in the tumor microenvironment as compared to the contralateral normal tonsil or PBMC (p = 0.01) (Supplementary Figure 1a ). The infiltrating Tregs seemed to be tumor specific since this population was not as high in a non-cancer microenvironment despite high levels of background inflammation within benign tonsil specimens (p = 0.02) (Supplementary Figure 1b) . These data suggest that HPV-HNSCCs have a suppressive tumor microenvironment, and modulation of these enriched inhibitory Tregs may facilitate successful antitumor immunotherapy. CTX has been used to target the Treg population both in the preclinical and clinical setting [9, 14, 15] . The immunopotentiating effects of CTX in combination with immunotherapy have been demonstrated at a single dose of 50 mg/kg in a preclinical model [13] . Therefore, we evaluated the effects of CTX in the TC-1 tumor model as well as evaluated the combination of a single i.p. dose of CTX with the CRT/E7 DNA vaccine (Fig. 1a) . Other groups included treatment with CTX alone, CRT/E7 DNA vaccination alone, or no treatment. We found that CTX in combination with the CRT/E7 vaccine resulted in the greatest antitumor effect when compared to single modality therapy (p \ 0.05) (Fig. 1b) . A synergistic effect was also observed with improved survival in mice receiving the combination therapy (Fig. 1c) .
Transient reduction in regulatory T cells with single-dose CTX therapy
We then evaluated the effect of single-dose CTX on the CD4 ? FoxP3 ? Treg population in the tumor microenvironment. Five-to eight-week-old C57BL/6 mice (four mice per group) were injected with 1 9 10 5 TC-1 tumor cells per mouse. Fifteen days after tumor inoculation, the mice were treated with either a single i.p. dose of CTX (50 mg/kg) or saline and the frequency of CD4
? FoxP3 ? Tregs evaluated at different time points. Four days after CTX treatment, mice were sacrificed and a reduction in CD4
? FoxP3
?
Tregs was observed in the tumor microenvironment of the CTX-treated group as compared with the saline-treated group (p \ 0.001) (Fig. 1d) (Fig. 1e) . These findings suggest that the effects of CTX on Tregs are transient, and there is a repopulation of Tregs in the tumor microenvironment several days after CTX administration.
Dose titration of daily administration of CTX for sustained targeting of regulatory T cells and synergistic effect with CRT/E7 vaccine Given the observed repopulation of Tregs within the tumor microenvironment after cessation of CTX treatment, we wanted to evaluate the effects of daily low-dose CTX administration on Treg frequency within the tumors. Therefore, we first performed dose titration studies to determine the optimal dose for daily CTX administration. We ensured that the doses that would be evaluated were feasible for human translation. As a result, the maximum dose evaluated was 20 mg/kg in the mouse, which is equivalent to 50-60 mg/m 2 for humans, a dose that has been used in prior human studies [23, 24] . Mice were inoculated with tumor and, subsequently, treated with i.p. administration of 5, 10, or 20 mg/kg of daily CTX. Tumor volume and survival were measured biweekly (n = 5, Fig. 2a and b) . We found that the daily dose of 10 and 20 mg/kg resulted in comparable antitumor effects (p value = 0.46), whereas the daily dose of 5 mg/kg had minimal antitumor effect and was similar to those effects observed in mice that received no treatment (p = 0.197).
Therefore, we further pursued the doses of 10 and 20 mg/kg for daily CTX administration in combination with the CRT/E7 vaccine. We found that the combination of CRT/E7 vaccine with daily CTX administration of either 10 or 20 mg/kg resulted in comparable enhanced antitumor effects and improved survival as compared to single modality therapy alone (data not shown). However, differences were observed in the lymphocyte population between these two CTX-dosing groups. We found a reduction in the CD4
? FoxP3 ? Treg frequency in both the spleen and tumors of mice treated with daily CTX (independent of dosing with either 10 or 20 mg/kg) as compared to the untreated groups (Supplementary Figure 2a) suggesting that daily CTX treatment achieved a sustained reduction in the Treg population. However, when we evaluated E7-tetramer-specific CD8
? T-cell responses to vaccination in the setting of CTX therapy, we found that daily administration of 20 mg/kg of CTX resulted in blunting of HPV16 E7 peptide-specific CD8
? T cells in both the spleen and tumor (Supplementary Figure 2b) . Therefore, the higher daily dose administration of 20 mg/kg of CTX was eradicating both the Treg and vaccine-induced cytotoxic CD8
? T-cell population, thereby neutralizing the immunomodulatory benefit of administering CTX in combination with vaccine. The highest frequency of HPV-16 E7 peptide-specific CD8
? T cells was observed in mice treated with the combination of daily 10 mg/kg of CTX with the CRT/E7 vaccine suggesting that this is the optimal daily dosing of CTX to potentiate the effects of the CRT/ E7 vaccine.
Direct comparison of daily and single dose of CTX in combination with CRT/E7 vaccine After determining the optimal daily dose of CTX that resulted in sustained Treg targeting and synergistic effect with vaccination, we performed a direct comparison of daily dosing of 10 mg/kg of CTX and single induction dose of 50 mg/kg of CTX in combination with vaccination (Fig. 3a) . TC-1 tumor-bearing mice were treated with 5 TC-1 tumor cells per mouse were injected s.c. in the right flank of 5-to 8-weekold C57BL/6 mice (five mice per group) and treated with the regimen described in a. Eight days after the last CTX administration, tumorinfiltrating lymphocytes were prepared and surface stained with antimouse CD4 followed by intracellular Foxp3 staining either a daily dose of 10 mg/kg of CTX with CRT/E7 DNA vaccine on days 9, 16, and 23 or with single administration of 50 mg/kg of CTX followed by CRT/E7 DNA vaccine 24 h later, and this treatment was repeated weekly for a total of three treatments. We found that mice (n = 10 per group) receiving the combination of CTX (independent of a single-or daily-dosing schedule) in combination with the CRT/E7 vaccine had the best antitumor effects as compared to CTX alone, CRT/E7 vaccine alone, or no treatment (p \ 0.05) (Fig. 3b) . Kaplan-Meier survival analysis demonstrated improved outcomes with combination therapy over single modality therapy (p \ 0.05) (Fig. 3c) . No significant difference between daily-and single-dose CTX administration in combination with the CRT/E7 vaccine was observed.
Effect of daily and single dose of CTX in combination with vaccine on Tregs, myeloid-derived suppressor cells, and antigen-specific CD8
? T cells
We evaluated the frequency of CD4 ? FoxP3 ? regulatory T cells in the various treatment groups 7 days after the last vaccination. We found that daily administration of 10 mg/kg of CTX in combination with vaccine resulted in a significant reduction in tumor infiltrating CD4
? FoxP3 ? regulatory T cells as compared to a single dose of 50 mg/kg CTX in combination with vaccine or controls (p = 0.001 and 0.0002, respectively) ( Fig. 4d and e) . No significant reduction in Tregs was observed between single dose of 50 mg/kg CTX in combination with vaccine as compared to controls (p = 0.336). This is consistent with the observation that there is a repopulation of Tregs several days after CTX administration. Data from cancer patients have shown that a high CD8
? /Treg ratio is associated with a favorable prognosis in ovarian cancer [25] and cervical cancer [26] , suggesting that the ratio of CD8
? /Treg is a better marker to reflect the immune suppression induced by Tregs in the tumor microenvironment. We found that within the spleen (Fig. 4c) and tumor (Fig. 4f) , both daily and single dose of CTX in combination with DNA vaccination resulted in a significantly higher CD8
? /Treg ratio (p \ 0.05). Therefore, our results demonstrated that daily or single dose of CTX in combination with vaccination generated a favorable tumor microenvironment for the effect of vaccine-induced CD8
? T cells. CTX has been shown to increase the levels of myeloid cells and MDSCs when administered at high doses [27, 28] . We also found that the mice treated with single dose of CTX at 50 mg/kg significantly increased the frequency of MDSCs (CD11b ? Gr-1 ? ) compared to control mice (p = 0.002) (Fig. 5a and b) , whereas daily dose of 10 mg/kg did not significantly increase the frequency of MDSCs (p = 0.867) (Fig. 5a and b) . The combination of CTX and DNA vaccination significantly increased the tumor infiltration of CD11b
? myeloid cells when compared to single treatment (p \ 0.05) (Fig. 5c ). More importantly, we found that combination treatment significantly increased the ratio of CD3
? CD8 ? T cells/CD11b ? Gr-1 ? MDSCs compared to control mice (p \ 0.01) (Fig. 5d) . Taken together, our data suggest that daily or single dose of CTX changed the tumor microenvironment to favor CD8
? T-cell responses. We then evaluated vaccine induced HPV-16 E7 antigenspecific CD8
? T-cell frequencies. We found that in the spleen, single-dose administration of 50 mg/kg of CTX prior to vaccination resulted in higher levels of antigenspecific CD8
? T cells as compared to daily-dose administration of 10 mg/kg of CTX with vaccination or to vaccination alone (p = 0.007 and p = 0.008, respectively) ( Fig. 6a and b ). There were also higher levels of antigenspecific CD8
? T cells with single low-dose administration of CTX as compared to daily dosing within the tumors (p = 0.335) (Fig. 6c and d) . However, this did not reach statistical significance possibly due to the small volume of tumors and TILs present in the combination treatment group of CTX and CRT/E7 vaccination (Fig. 3b) .
Discussion
Increased frequencies of Tregs are present in the microenvironment of HPV-HNSCC and may be dampening Supplementary Figure 1) . Therefore, there is a role in developing strategies to address these immunosuppressive cells in the setting of immunotherapeutic strategies aimed to enhance cytotoxic T cell-mediated responses. Treg-depleting agents, including CTX, anti-CD25, and anti-GITR monoclonal antibody, have been used to enhance antigen-specific cytotoxic T cells [29] . In the current study, we evaluated the role of CTX in combination with a therapeutic HPV-16 DNA vaccine, pNGVL4a-CRT/E7(detox), and demonstrated that CTX can act synergistically with the CRT/E7 vaccine to elicit potent antitumor responses, which are greater than that observed with monotherapy alone. The potent antitumor responses were attributed to the reduction in Treg frequency and increased infiltration of HPV16 E7-specific CD8
? T cells, which led to higher ratios of CD8 ? /Treg and CD8
? /CD11b ? Gr-1 ? MDSC. The antitumor effects of metronomic dosing of CTX have been attributed to its immunomodulatory function and its anti-angiogenic effects on tumor growth [30] . No difference in tumor volume was observed between the CTX-treated nude mice as compared to untreated nude mice (Supplementary Figure 3) suggesting that the antitumor effects observed with the administered doses of CTX were from its immunomodulatory rather than cytotoxic or anti-angiogenic properties.
Multiple dosing regimens have been evaluated for CTX administration in a variety of tumor models. Preconditioning with CTX 24 h prior to immunotherapy was found to be optimal in adoptive tumor-specific T-cell transfer experiments in preclinical models [13, 31] . However, single dose preconditioning with CTX may only have a transient effect on the Treg population. Berraondo et al. [32] evaluated the administration of CTX 24 h prior to vaccination with an E7 protein vaccine in a HPV murine tumor model, and although they demonstrated an enhanced antitumor effect with administration of CTX, they observed a recovery and expansion of CD4
? FoxP3 ? T cells 11 days after therapy. We found a similar repopulation of Tregs within the tumor microenvironment when assayed as early as 7 days after CTX administration.
Therefore, several groups have evaluated metronomic dosing of CTX in order to achieve sustained targeting of Tregs. Daily CTX administration has been demonstrated to have antitumor effects in both preclinical and clinical studies [33] [34] [35] [36] [37] . Daily oral administration of CTX, ranging from 50 to 200 mg total daily dose, was found to be safe in clinical trials for patients with soft tissue sarcomas, prostate, endometrial, and breast cancers [24, [38] [39] [40] [41] . Furthermore, combination of metronomic dosing of CTX with DNA vaccination in a melanoma model resulted in enhanced antitumor activity [42] , and after 1 month of treatment, metronomic dosing was found to result in a persistent selective depletion of Tregs [43] .
Increased levels of MDSCs after CTX administration at high doses have been reported previously [27, 28] . We found that only single low dose of 50 mg/kg significantly increased ? myeloid cells in the tumor. However, this increased accumulation is overcome by the more significant infiltration of cytotoxic CD8
? T cells. Therefore, the inhibitory effect of MDSCs after CTX administration is likely compensated by the significantly higher CD3
? CD8 ? T cell/CD11b ? Gr-1 ? MDSC ratios induced after vaccination.
There is a wide range of dosing regimens of CTX in the current literature, and a systematic approach to determine the appropriate dose and frequency of CTX in combination with immunotherapy has not yet been performed. Therefore, we performed a direct comparison between a single dose of CTX and daily dosing of CTX in combination with an HPV DNA vaccine to determine the optimal dosing regimen for translation in an upcoming clinical trial in HPV-HNSCC patients.
Emens et al. [44] reported a threshold for the immunopotentiating effects of CTX when administered as a preconditioning single dose based on suppression of humoral activity. In an evaluation of intravenous CTX in combination with vaccine therapy in breast cancer patients, they determined 200 mg/m 2 as the threshold dose above which immunosuppression was observed [44] . Based on this report in humans and other dose response reports in preclinical models, a single dose of 50 mg/kg of CTX (equivalent to 200 mg/m 2 in humans) prior to DNA vaccination seemed to be an appropriate dose to evaluate in our murine tumor model [13] . However, when determining the appropriate metronomic dosing of CTX, the literature was much more varied. Therefore, we first performed a dose titration of daily administration of CTX. We demonstrated a similar dosing limitation for daily administration of CTX based on effector T-cell responses. We found that daily dosing with 20 mg/kg of CTX, a dose equivalent to that used in previous human clinical trials (50-60 mg/m 2 for a 60 kg male is equivalent to 19.5-20 mg/kg in a 20 g mouse http://dtp.nci.nih.gov), resulted in blunting of the animals ability to generate antigen-specific cytotoxic T cells. Rather, we found that the optimal dosing for daily CTX administration was 10 mg/kg, which is equivalent to 55 mg/day in a 60 kg patient or 30 mg/m 2 . We compared the single dose of 50 mg/kg of CTX (human equivalent of 200 mg/m 2 ) prior to DNA vaccination Gr-1 ? myeloid-derived suppressor cells (MDSC) after treatment of CTX in combination with HPV vaccine. The TC-1 tumorbearing mice were treated as described in Fig. 3a to daily dosing of 10 mg/kg of CTX (human equivalent of 30 mg/m 2 ) with DNA vaccination and found comparable levels of antitumor effect and survival. Daily dosing of CTX resulted in sustained targeting of Tregs within the tumor microenvironment. However, with the daily dosing of CTX, we also observed a trend toward decreased antigen-specific T cells within the tumors suggesting that daily CTX administration may not only be targeting the Treg population but also the antigen-specific T cells elicited through vaccination. Therefore, single-dose administration of CTX, as compared to daily dosing, in combination with vaccination may be an appropriate regimen for human translation.
In conclusion, an increasing number of immunotherapeutic strategies are being evaluated in HPV-related cancers, and Tregs within the tumor microenvironment of HPV-HNSCC may impact the efficacy of these immunotherapeutic strategies. The combination of CTX and a therapeutic HPV DNA vaccine resulted in enhanced antitumor effects, antigen-specific immune responses, and improved overall survival as compared to monotherapy alone. There are several advantages to single-dose administration of CTX as compared to daily administration. Patient compliance with drug intake may be improved with single-dose administration. In addition, there were observed trends that dose limiting effector T-cell suppression ? T cells in HPV tumor-bearing mice. The TC-1 tumor-bearing mice were treated as described in Fig. 4a . Briefly, 7 days after last vaccination, single cells were prepared from spleen and tumor. Splenocytes (5 9 10 6 ) or single-cell suspensions from TC-1 tumors (2 9 10 6 ) from each experimental group were incubated for 20 h with 1 lg/ml of E7aa49-57 peptide (RAHYNIVTF) in the presence of GolgiPlug (BD Pharmingen, San Diego, CA). The stimulated splenocytes were washed with FACS wash buffer (PBS ? 0.5 % BSA) and stained with PE-conjugated anti-mouse CD8a. The cells were then fixed using the Cytofix/Cytoperm kit according to the manufacturer's instruction. Intracellular IFN-c was stained with FITC-conjugated anti-mouse IFN-c antibody. Flow cytometry analysis was performed using the FACSCalibur with CELLQuest software. a Representative flow cytometry data of HPV16 E7aa49-57 peptide-specific CD8
? T cells from spleen. b Summary of the flow cytometry data of HPV16 E7aa49-57 peptide-specific CD8
? T cells from spleen. c Representative flow cytometry data of HPV16 E7aa49-57 peptide-specific CD8 ? T cells from s tumor-infiltrating lymphocytes. d Summary of the flow cytometry data of HPV16 E7aa49-57 peptide-specific CD8
? T cells from tumor-infiltrating lymphocytes occurred with daily dosing of CTX, which can neutralize any of its immunomodulatory benefits. This study supports the application of single-dose CTX administration in combination with immunotherapeutic strategies to address the inhibitory Treg population that may dampen vaccineinduced clinical responses.
